BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.

When a muscle contracts, the parts of a sarcomere "shorten" and come closer together. Each cardiac muscle cell can have over 5,000 sarcomeres, which compounds both the shortening and relaxation events ...

This study investigates the role of a key interaction between Tropomyosin (Tpm) and Troponin T (TnT) in the regulation of cardiac muscle contraction, with a particular focus on understanding ...

Researchers have investigated the effect of increased cell temperature on the contractility of skeletal muscle and cardiac muscle by heating the muscle proteins using advanced microscopical techniques ...